Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IOVANASDAQ:NVAXNASDAQ:OYSTNASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIOVAIovance Biotherapeutics$3.13+1.0%$3.43$2.70▼$13.88$1.05B1.067.72 million shs8.24 million shsNVAXNovavax$5.95-2.0%$6.92$4.43▼$23.86$957.02M3.218.39 million shs4.50 million shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsVIRVir Biotechnology$5.61-0.4%$6.39$4.95▼$14.45$774.54M1.361.34 million shs1.26 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIOVAIovance Biotherapeutics-11.29%-12.78%+3.50%-49.10%-77.63%NVAXNovavax-3.19%-5.45%-2.72%-29.42%+27.52%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%VIRVir Biotechnology-8.46%-5.85%+0.90%-43.98%-44.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIOVAIovance Biotherapeutics4.6464 of 5 stars4.43.00.04.23.22.50.6NVAXNovavax3.4921 of 5 stars3.21.00.04.72.60.80.6OYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology2.9911 of 5 stars3.41.00.00.03.53.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIOVAIovance Biotherapeutics 2.89Moderate Buy$18.22482.18% UpsideNVAXNovavax 2.43Hold$18.00202.52% UpsideOYSTOyster Point Pharma 0.00N/AN/AN/AVIRVir Biotechnology 2.86Moderate Buy$33.57498.42% UpsideCurrent Analyst Ratings BreakdownLatest OYST, IOVA, NVAX, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $16.004/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.004/14/2025IOVAIovance BiotherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$22.00 ➝ $5.003/3/2025IOVAIovance BiotherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $15.003/3/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.003/3/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $30.002/28/2025IOVAIovance BiotherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$24.00 ➝ $20.002/28/2025IOVAIovance BiotherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$7.50 ➝ $6.002/28/2025IOVAIovance BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.002/28/2025NVAXNovavaxBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.002/28/2025VIRVir BiotechnologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $31.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIOVAIovance Biotherapeutics$164.07M6.37N/AN/A$2.28 per share1.37NVAXNovavax$682.16M1.40N/AN/A($6.04) per share-0.99OYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94VIRVir Biotechnology$63.71M12.16N/AN/A$11.82 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIOVAIovance Biotherapeutics-$444.04M-$1.30N/AN/AN/A-451.25%-58.43%-45.48%5/8/2025 (Estimated)NVAXNovavax-$545.06M-$1.33N/A74.382.85-32.18%N/A-17.05%5/9/2025 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/AVIRVir Biotechnology-$615.06M-$3.82N/AN/AN/A-678.40%-36.71%-31.00%5/7/2025 (Confirmed)Latest OYST, IOVA, NVAX, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NVAXNovavax$0.19N/AN/AN/A$204.08 millionN/A5/8/2025Q1 2025IOVAIovance Biotherapeutics-$0.25N/AN/AN/A$83.40 millionN/A5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 millionN/A2/27/2025Q4 2024IOVAIovance Biotherapeutics-$0.26-$0.26N/A-$0.26$72.17 million$73.69 million2/27/2025Q4 2024NVAXNovavax-$0.75-$0.51+$0.24-$0.51$85.48 million$88.31 million2/26/2025Q4 2024VIRVir Biotechnology-$0.85-$0.76+$0.09-$0.76$8.14 million$12.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIOVAIovance BiotherapeuticsN/A4.223.90NVAXNovavaxN/A0.930.93OYSTOyster Point Pharma8.493.353.11VIRVir BiotechnologyN/A8.948.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIOVAIovance Biotherapeutics77.03%NVAXNovavax53.04%OYSTOyster Point Pharma96.70%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipIOVAIovance Biotherapeutics12.10%NVAXNovavax1.00%OYSTOyster Point Pharma17.90%VIRVir Biotechnology15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIOVAIovance Biotherapeutics500333.93 million267.90 millionOptionableNVAXNovavax1,990160.84 million158.58 millionOptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionableVIRVir Biotechnology580138.06 million116.24 millionOptionableOYST, IOVA, NVAX, and VIR HeadlinesRecent News About These CompaniesVir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call TranscriptMay 7 at 11:31 PM | seekingalpha.comVir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue EstimatesMay 7 at 7:20 PM | zacks.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 7 at 4:05 PM | businesswire.com1,084,539 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Baker BROS. Advisors LPMay 6 at 7:39 AM | marketbeat.comWells Fargo & Company MN Has $387,000 Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)May 6 at 3:20 AM | marketbeat.comBarclays PLC Has $1.62 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)May 5 at 3:27 AM | marketbeat.comSusquehanna Fundamental Investments LLC Invests $1.48 Million in Vir Biotechnology, Inc. (NASDAQ:VIR)May 3, 2025 | marketbeat.comTower Research Capital LLC TRC Has $451,000 Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)May 2, 2025 | marketbeat.comVir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025April 30, 2025 | businesswire.comVir Biotechnology (VIR) to Release Earnings on ThursdayApril 26, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by AnalystsApril 25, 2025 | marketbeat.comVir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025April 24, 2025 | businesswire.comVir Biotechnology (NASDAQ:VIR) Shares Up 5.5% - Here's What HappenedApril 23, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Up 28.3% in MarchApril 21, 2025 | marketbeat.comWalleye Capital LLC Increases Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)April 20, 2025 | marketbeat.comRenaissance Technologies LLC Buys 55,300 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)April 20, 2025 | marketbeat.comQuinn Opportunity Partners LLC Purchases Shares of 65,976 Vir Biotechnology, Inc. (NASDAQ:VIR)April 14, 2025 | marketbeat.comNew Mpro inhibitors revealed in Vir Biotechnology patentApril 11, 2025 | bioworld.comExodusPoint Capital Management LP Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)April 11, 2025 | marketbeat.comVir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Here's WhyApril 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOYST, IOVA, NVAX, and VIR Company DescriptionsIovance Biotherapeutics NASDAQ:IOVA$3.13 +0.03 (+0.97%) Closing price 04:00 PM EasternExtended Trading$3.13 0.00 (0.00%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Novavax NASDAQ:NVAX$5.95 -0.12 (-1.98%) Closing price 04:00 PM EasternExtended Trading$5.95 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Oyster Point Pharma NASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Vir Biotechnology NASDAQ:VIR$5.61 -0.02 (-0.36%) Closing price 04:00 PM EasternExtended Trading$5.51 -0.10 (-1.76%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
